FolioStart free

Medicine · Literature

Research papers on Statins and heart disease

Recent and highly-cited academic work on statins and heart disease, gathered from Semantic Scholar, CrossRef and OpenAlex.

Search all 200M+ papers on this topic, free →Or track new statins and heart disease papers automatically as they publish

  1. Statins for the primary prevention of cardiovascular disease

    Fiona C. Taylor, Mark D. Huffman, Ana Filipa Macedo, et al. · 2013 · Cochrane Database of Systematic Reviews · 1,934 citations

    BACKGROUND: Reducing high blood cholesterol, a risk factor for cardiovascular disease (CVD) events in people with and without a past history of CVD is an important goal of pharmacotherapy. Statins are the first-choice agents. Previous reviews of the effects of statins have highlighted their benefits in people with CVD. The case for primary prevention was uncertain when the last version of this review was published (2011) and in light of new data an update of this review is required. OBJECTIVES: To assess the effects, both harms and benefits, of statins in people with no history of CVD. SEARCH METHODS: To avoid duplication of effort, we checked reference lists of previous systematic reviews.

    Save this paper

  2. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults

    US Preventive Services Task Force, Kirsten B. Bibbins-Domingo, David C. Grossman, et al. · 2016 · JAMA · 590 citations

    Importance: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults. Objective: To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies

    Save this paper

  3. Statins for Prevention of Cardiovascular Disease in Adults

    Roger Chou, Tracy Dana, Ian Blazina, et al. · 2016 · JAMA · 568 citations

    Importance: Cardiovascular disease (CVD), the leading cause of mortality and morbidity in the United States, may be potentially preventable with statin therapy. Objective: To systematically review benefits and harms of statins for prevention of CVD to inform the US Preventive Services Task Force. Data Sources: Ovid MEDLINE (from 1946), Cochrane Central Register of Controlled Trials (from 1991), and Cochrane Database of Systematic Reviews (from 2005) to June 2016. Study Selection: Randomized clinical trials of statins vs placebo, fixed-dose vs titrated statins, and higher- vs lower-intensity statins in adults without prior cardiovascular events. Data Extraction and Synthesis: One investigator

    Save this paper

  5. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults

    US Preventive Services Task Force, Carol M. Mangione, Michael J. Barry, et al. · 2022 · JAMA · 392 citations

    Importance: Cardiovascular disease (CVD) is the leading cause of morbidity and death in the US and is the cause of more than 1 of every 4 deaths. Coronary heart disease is the single leading cause of death and accounts for 43% of deaths attributable to CVD in the US. In 2019, an estimated 558 000 deaths were caused by coronary heart disease and 109 000 deaths were caused by ischemic stroke. Objective: To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on the benefits and harms of statins for reducing CVD-related morbidity or mortality or all-cause mortality. Population: Adults 40 years or older without a history of known CV

    Save this paper

  6. Primary Prevention of Cardiovascular Diseases With Statin Therapy

    Paaladinesh Thavendiranathan · 2006 · Archives of Internal Medicine · 351 citations

    BACKGROUND: While the role of hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins) in secondary prevention of cardiovascular (CV) events and mortality is established, their value for primary prevention is less clear. To clarify the role of statins for patients without CV disease, we performed a meta-analysis of randomized controlled trials (RCTs). METHODS: MEDLINE, EMBASE, Cochrane Collaboration, and American College of Physicians Journal Club databases were searched for RCTs published between 1966 and June 2005. We included RCTs with follow-up of 1 year or longer, more than 100 major CV events, and 80% or more of the population without CV disease. From each trial, demographic da

    Save this paper

  7. Statins for the primary prevention of cardiovascular disease

    Shah B J Ebrahim, F. C. Taylor, P Brindle · 2014 · BMJ · 333 citations

    How safe are they?Use of statins by low risk patients has been criticised on the grounds that their benefits do not outweigh their harms 12 and debated. 13 14However, all cause mortality in people taking statins with no pre-existing cardiovascular disease is reduced (table⇓), indicating that any unintended life threatening effects are outweighed by their beneficial impact on cardiovascular disease, although this evidence is not strong. 15Earlier concerns about cancer risk are unfounded. 16However, other unintended effects

    Save this paper

  9. Statins for the primary prevention of cardiovascular disease

    Fiona C. Taylor, Kirsten J. Ward, Theresa HM Moore, et al. · 2011 · Cochrane Database of Systematic Reviews · 305 citations

    BACKGROUND: Reducing high blood cholesterol, a risk factor for cardiovascular disease (CVD) events in people with and without a past history of coronary heart disease (CHD) is an important goal of pharmacotherapy. Statins are the first-choice agents. Previous reviews of the effects of statins have highlighted their benefits in people with coronary artery disease. The case for primary prevention, however, is less clear. OBJECTIVES: To assess the effects, both harms and benefits, of statins in people with no history of CVD. SEARCH STRATEGY: To avoid duplication of effort, we checked reference lists of previous systematic reviews. We searched the Cochrane Central Register of Controlled Trials (

    Save this paper

  10. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults

    Roger Chou, Amy G. Cantor, Tracy Dana, et al. · 2022 · JAMA · 285 citations

    Importance: A 2016 review for the US Preventive Services Task Force (USPSTF) found use of statins for primary prevention of cardiovascular disease (CVD) was associated with reduced mortality and cardiovascular outcomes. Objective: To update the 2016 review on statins for primary prevention of CVD to inform the USPSTF. Data Sources: Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews (to November 2021); surveillance through May 20, 2022. Study Selection: Randomized clinical trials on statins vs placebo or no statin and statin intensity in adults without prior cardiovascular events; large cohort studies on harms. Data Extraction and Synthes

    Save this paper

  12. Statins for primary prevention of cardiovascular disease

    Camille Michael Minder, Roger Scott Blumenthal, Michael Joseph Blaha · 2013 · Current Opinion in Cardiology · 67 citations

    PURPOSE OF REVIEW: Statins significantly reduce cardiovascular morbidity and mortality in patients with and without coronary heart disease. Recently, much debate has focused on use of statins for primary prevention following a class-wide safety label change by the US Food and Drug Administration amidst concerns of worsened hyperglycemia. Here, we review the evidence for statins in primary prevention and offer guidance for their appropriate use. RECENT FINDINGS: Two meta-analyses published since 2012 unequivocally support statins for primary prevention. Data from the Cholesterol Treatment Trialists' Collaborators demonstrated a 9% [relative risk (RR) 0.91, 95% confidence interval (CI) 0.85-0.

    Save this paper

Write your paper with these sources

Folio is the integrity-first research workspace: search 200M+ papers, save sources, and write with citations that format themselves. Free for students and researchers.

Start writing free →